Since SK bioscience acquired a 60% stake in the CDMO, the company has undertaken a “full-scale drive” to expand its business in vaccines and biopharmaceuticals.
Construction is set to begin in spring 2026, with the two facilities in North Chicago expected to be fully operational in 2029 and supported by 300 new hires.